In contrast, 268 patients received PD-L1 inhibitors, which were distributed across four tumor types: SCLC (46.6%, 125/2255), NSCLC (42.9%, 115/2255), BTC (5.6%, 15/2255), and HCC (4.9%, 13/2255). This evidence concerns the gene CD274 and hepatocellular carcinoma.